Serum alpha 1-acid glycoprotein in epithelial ovarian cancer

Gynecol Oncol. 1988 Mar;29(3):305-8. doi: 10.1016/0090-8258(88)90229-6.

Abstract

Fifty-six patients with ovarian adenocarcinoma receiving chemotherapy were monitored with serum alpha 1-acid glycoprotein (AGP) levels. The mean and standard deviation of serum AGP levels for 63 healthy controls were 0.88 +/- 0.469 mg/ml. A serum level above 1.80 mg/ml was considered as above normal level. Five patients had evidence of persistent ovarian carcinoma and had elevated AGP levels. Sixteen patients had normal serum AGP levels and had no evidence of persistent ovarian cancer at second-look laparotomy. However, 35 patients had false-negative AGP levels at the time they had persistent tumor. Although the specificity of the AGP level was 100%, the sensitivity was only 12.5% and the overall accuracy 37%. Therefore, it would appear that serum AGP levels are not of value in monitoring patients with ovarian adenocarcinoma.

MeSH terms

  • Adenocarcinoma / blood*
  • Adenocarcinoma / drug therapy
  • Biomarkers, Tumor / blood*
  • Cisplatin / therapeutic use
  • Double-Blind Method
  • False Negative Reactions
  • Female
  • Humans
  • Orosomucoid / analysis*
  • Ovarian Neoplasms / blood*
  • Ovarian Neoplasms / drug therapy

Substances

  • Biomarkers, Tumor
  • Orosomucoid
  • Cisplatin